205 related articles for article (PubMed ID: 33685041)
1. [Clinical characteristics of "classical" and "non-classical" paraneoplastic neurological syndrome].
Lyu XY; Wang GP; Tang QQ; Cheng ZZ; Gui W; Tian YH
Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(9):615-619. PubMed ID: 33685041
[No Abstract] [Full Text] [Related]
2. "Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected.
Berger B; Bischler P; Dersch R; Hottenrott T; Rauer S; Stich O
J Neurol Sci; 2015 May; 352(1-2):58-61. PubMed ID: 25824848
[TBL] [Abstract][Full Text] [Related]
3. A single center retrospective study of paraneoplastic neurological syndromes with positive onconeural antibodies.
Fu P; He L; Tang N; Nie Q; Li Z
J Clin Neurosci; 2021 Jul; 89():336-342. PubMed ID: 34119290
[TBL] [Abstract][Full Text] [Related]
4. Paraneoplastic neurological syndromes with onconeural antibodies: A single center retrospective study.
Oliveira V; Videira G; Samões R; Carneiro P; Neves E; Santos E
J Neurol Sci; 2020 Nov; 418():117103. PubMed ID: 32877801
[TBL] [Abstract][Full Text] [Related]
5. Paraneoplastic neurological syndromes of the central nervous system: a single institution 7-year case series.
Giammello F; Galletta K; Grillo F; Brizzi T; Cavallaro M; Mormina E; Scelzo E; Allegra C; Stancanelli C; Rodolico C; Musumeci O; Toscano A; Granata F
Acta Neurol Belg; 2023 Aug; 123(4):1355-1369. PubMed ID: 36884202
[TBL] [Abstract][Full Text] [Related]
6. Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies.
Raspotnig M; Vedeler C; Storstein A
J Neurol Sci; 2015 Jan; 348(1-2):41-5. PubMed ID: 25467140
[TBL] [Abstract][Full Text] [Related]
7. Onconeural antibodies in patients with neurological symptoms: detection and clinical significance.
Raspotnig M; Vedeler CA; Storstein A
Acta Neurol Scand Suppl; 2011; (191):83-8. PubMed ID: 21711262
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal synthesis of onconeural antibodies in patients with paraneoplastic syndromes.
Corsini E; Gaviani P; Chiapparini L; Lazzaroni M; Ciusani E; Bisogno R; Silvani A; Salmaggi A; Bernardi G
J Neuroimmunol; 2016 Jan; 290():119-22. PubMed ID: 26711581
[TBL] [Abstract][Full Text] [Related]
9. [Neurological syndromes, encephalitis].
Yamamoto T; Tsuji S
Gan To Kagaku Ryoho; 2010 Jun; 37(6):995-1005. PubMed ID: 20567100
[TBL] [Abstract][Full Text] [Related]
10. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.
Ariño H; Höftberger R; Gresa-Arribas N; Martínez-Hernández E; Armangue T; Kruer MC; Arpa J; Domingo J; Rojc B; Bataller L; Saiz A; Dalmau J; Graus F
JAMA Neurol; 2015 Aug; 72(8):874-81. PubMed ID: 26099072
[TBL] [Abstract][Full Text] [Related]
11. Clinical approach to diagnosis of paraneoplastic neurologic syndromes.
Graus F
Handb Clin Neurol; 2024; 200():79-96. PubMed ID: 38494298
[TBL] [Abstract][Full Text] [Related]
12. Paraneoplastic neurological syndromes associated with non-Hodgkin lymphoma: a case series.
Dinoto A; Cheli M; Catalan M; Olivo S; Scali I; Bertolotti C; Sartori A; Manganotti P
Neurol Sci; 2022 Mar; 43(3):2077-2079. PubMed ID: 35000013
[TBL] [Abstract][Full Text] [Related]
13. Neurological paraneoplastic syndromes in lung cancer patients.
Stefens-Stawna P; Piorunek T; Gabryel-Batura H; Kozubski W; Michalak S
Adv Exp Med Biol; 2013; 756():333-9. PubMed ID: 22836651
[TBL] [Abstract][Full Text] [Related]
14. Recommended diagnostic criteria for paraneoplastic neurological syndromes.
Graus F; Delattre JY; Antoine JC; Dalmau J; Giometto B; Grisold W; Honnorat J; Smitt PS; Vedeler Ch; Verschuuren JJ; Vincent A; Voltz R
J Neurol Neurosurg Psychiatry; 2004 Aug; 75(8):1135-40. PubMed ID: 15258215
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.
Storstein A; Raspotnig M; Vitaliani R; Giometto B; Graus F; Grisold W; Honnorat J; Vedeler CA
J Neurol; 2016 May; 263(5):1001-1007. PubMed ID: 27007485
[TBL] [Abstract][Full Text] [Related]
16. Utility of 18F-FDG-PET/CT in patients suspected of paraneoplastic neurological syndrome: importance of risk classification.
Pena Pardo FJ; García Vicente AM; Amo-Salas M; López-Fidalgo JF; Garrido Robles JA; de Ayala Fernández JÁ; Del Saz Saucedo P; Muñoz Pasadas M; Soriano Castrejón A
Clin Transl Oncol; 2017 Jan; 19(1):111-118. PubMed ID: 27139696
[TBL] [Abstract][Full Text] [Related]
17. Clinical Spectrum, Therapeutic Outcomes and Prognostic predictors in Paraneoplastic Neurological Syndromes - Experiences from a Tertiary Care Center in India.
Vijayaraghavan A; Alexander PT; Nair AV; Sivadasan A; Mani AM; Mathew D; Shaikh A; Benjamin RN; Prabhakar AT; Jude J; Mani S; Aaron S; Mathew V; Alexander M
Ann Indian Acad Neurol; 2021; 24(1):32-39. PubMed ID: 33911377
[TBL] [Abstract][Full Text] [Related]
18. [Paraneoplastic neurological syndrome and autoantibodies].
Hayashi Y; Inuzuka T
Brain Nerve; 2013 Apr; 65(4):385-93. PubMed ID: 23568986
[TBL] [Abstract][Full Text] [Related]
19. Incidence and spectrum of paraneoplastic neurological syndromes: single center study.
Kanikannan MA; Sirisha Y; Uppin MS; Jabeen SA; Kandadai RM; Sundaram C; Raghunadharao D; Borgohain R
J Neurooncol; 2015 Oct; 125(1):197-206. PubMed ID: 26307447
[TBL] [Abstract][Full Text] [Related]
20. Whole-body computed tomography as first-line imaging procedure to exclude cancer in patients with neurological suspicion of paraneoplastic syndromes: shall clinical practice adhere to recommendations?
Parillo M; Quattrocchi CC; Pilato F; Di Lazzaro V; Beomonte Zobel B
Radiography (Lond); 2023 Jan; 29(1):8-13. PubMed ID: 36179410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
